Zu besetzen sind die wissenschaftlichen Ausschüsse der Gentechnikkommission für die Dauer von fünf Jahren mit Beginn der Funktionsperiode per 1. November 2023, für die die ÖAW gemäß § 89 des Gentechnikgesetztes (GTG) das Nominierungsrecht ausübt.

Bewerbungen für die jeweils genau zu bezeichnenden Positionen können bis zum 3. März 2023 unter Beilage eines Lebenslaufes, Schriftenverzeichnisses und/oder Nachweis einer einschlägigen, praktischen Tätigkeit an uns (This email address is being protected from spambots. You need JavaScript enabled to view it.) gerichtet werden.

Öffentliche Ausschreibung: https://www.wienerzeitung.at/amtsblatt/aktuelle_ausgabe/artikel/?id=5084876

Mehr denn je braucht unsere Gesellschaft kluge Köpfe, die angesichts von Energie- und Klimakrise ihre Talente im Bereich Naturwissenschaft und Technik einbringen. Die FFG fördert im Auftrag des BMK auch im Jahr 2023 Sommerpraktika junger Menschen im Bereich Forschung, Technologie und Innovation.

In der Ausschreibung „Talente – Praktika für Schülerinnen und Schüler 2023“ werden insbesondere Praktika mit den Schwerpunkten „Energiewende“ und „Kreislaufwirtschaft“ gefördert. Praktika in anderen naturwissenschaftlich-technischen Themen können ebenfalls eingereicht werden. Die Einreichung erfolgt online via eCall.

Nähere Informationen zur Antragstellung für Unternehmen, Hochschulen und Außeruniversitäre Forschungseinrichtungen:

Ausschreibung Praktika 2023

Auf der Praktikabörse können interessierte Jugendliche ab Februar ihr Wunschpraktikum suchen und finden.

Praktikabörse

Bei Fragen stehen wir gerne unter 05 77 55 - 2222 zur Verfügung.

You can Submit Your Abstract or Apply for a Congress Attendance Grant to FEMS2023 until the deadline Wednesday 1 February. Reconnect with thousands of scientists from the microbiology community: combine, change, convene, continue, converse, create, and cross borders!

Taking place from 9 – 13 July 2023, make sure you take the opportunity to present your research at the 10th European Congress of Microbiologists in Hamburg, Germany.

View the programme day by day or at a glance, explore the session formats, and find out which sessions are inviting abstracts.

Main topics

• Environmental Microbiology & Ecology
• Biotechnology & Synthetic Microbiology
• Food Microbiology
• Infection Biology and Pathogens
• Infectious Diseases
• Taxonomy and systematics
• Genetics/genomics
• Virology
• Microbiology Education & Profession
• Molecular Microbiology and Biochemistry

Join us at FEMS2023!

We are happy to welcome our new company member: CYTIVA

We are a global provider of technologies and services that advance and accelerate the development, manufacture, and delivery of therapeutics. Our rich heritage dates back hundreds of years, and we got a fresh start in 2020 as a standalone operating company in the Danaher Corporation.

Homepage:     www.cytiva.com

We welcome our new company member:

acib is an international center of excellence in the field of industrial biotechnology. The research center develops sustainable, environmentally friendly, and economically and technically advanced processes for the biotech-, pharmaceutical- and chemical industries. In doing so, it takes nature’s methods and tools as its model. Within its partner network, acib cooperates with industry in order to transfer scientific results into efficient processes and innovative products, always for the benefit of humans, animals and the environment.

Homepage:         https://acib.at/

Die nächste Ausschreibungsrunde in Horizon Europe startet in Kürze mit einem Volumen von rund 5,5 Milliarden Euro an Förderungen. Die Europäische Kommission hat bereits vorläufige Versionen des Horizon Europe Arbeitsprogramms 2023/24 veröffentlicht (Änderungen noch möglich).
Bisher vorliegende Entwürfe und Veranstaltungen zu den kommenden Ausschreibungen: 

• Cluster 1 Gesundheit: Infotag 19. Jänner, Brokerage Event 20. Jänner
• Cluster 2 Kultur, Kreativität und Inklusive Gesellschaft: Infotag 17. Jänner, Brokerage Event 18. Jänner
• Cluster 4 Digitalisierung, Industrie & Weltraum: Infotage 12.-14. Dezember, Brokerage Events 8.-16. Dezember
• Cluster 5 Klima, Energie und Mobilität: Infotage 15.-16. Dezember, Brokerage Event 15. Dezember
• Cluster 6 Lebensmittel und natürliche Ressourcen: Infotage 13.-14. Dezember, Brokerage Event 19. Dezember
• Forschungsinfrastrukturen: Infotag 6. Dezember
• Ausweitung der Beteiligung und Verbreitung von Exzellenz (Widening): Infotag 12. Dezember

Für mehr Informationen: https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/home

About The International Microbiology Literacy Initiative (IMiLI)

Microbes and their activities have pervasive, remarkably profound and generally positive effects on the functioning, and thus health and well-being, of human beings, the whole of the biological world, and indeed the entire surface of the planet and its atmosphere. This necessitates their due consideration in decisions that are taken by individuals and families in everyday life, as well as by individuals and responsible bodies at all levels and stages of community, national and international planetary health assessment, planning, and the formulation of pertinent policies.  

However, knowledge of societally-relevant microbial activities, how they impact our lives, and how they may be harnessed for the benefit of humankind – microbiology literacy – is lacking in the general population, and in the subsets thereof that constitute the decision makers. The IMiLI contends that microbiology literacy in society is indispensable for informed personal decisions, policy development in government and business, and for knowledgeable input of societal stakeholders in such policymaking. An understanding of key microbial activities is as essential for transitioning from childhood to adulthood as some subjects currently taught at school, and must therefore be acquired during general education. The IMiLI is creating resources for a school curriculum of societally-relevant microbiology and calls upon microbiologists, microbiological learned societies and microbiology‐literate professionals to help develop child‐friendly, appealing teaching tools and materials, and convince educators, policy makers, business leaders and governmental and non‐governmental agencies to support and promote adoption of the curriculum by education authorities worldwide.

About FEMS

The Federation of European Microbiological Societies (FEMS) is a not-for-profit organization, established in 1974 to advance microbiology for the benefit of society in the areas of health, energy, food, materials, and the environment. We are committed to supporting microbiologists do their work; promoting the best in microbiology research and knowledge to the world and, bringing microbiologists together to share that knowledge. We reinvest our revenues into supporting microbiologists throughout their career, publishing and promoting scientific research in our journals and organizing events to bring scientists together.

About FEMS Lwoff Award for Achievements in Microbiology

Launched in 2000, the FEMS-Lwoff Award for Achievements in Microbiology rewards those that create high quality knowledge that helps to solve today’s societal problems around microbiology. It was named in honour of the 1st FEMS President (1974-1976), Professor André M. Lwoff. Previous winners include Prof Miroslav Radman and Prof Emmanuelle Charpentier.

Invitation to participate in an open consultation for the Strategic Research and Innovation Agenda (SRIA) in support for the European Partnership for Personalised Medicine, EP PerMed

It is our pleasure to inform you that the open consultation to validate and receive input for the Strategic Research and Innovation Agenda (SRIA) in support for the European Partnership for Personalised Medicine, EP PerMed, is launched. The outcome of the online consultation will be considered for the SRIA finalisation (02/2023) and the EP PerMed proposal (04/2023) as well as for developing activities and calls within the EP PerMed lifetime (Q4/2023-2030).

In preparation of the open consultation, the drafting group, with support of the European Commission, conducted almost 70 interviews with diverse stakeholders. Based on the interviews and consultation of strategic documents, a first set of 47 “Triplets of Action” was identified (further defined below). This list represents a first summary, adapted to a common format, but is not exhaustive and open for further input and refinement.

In a pre-final step (November 2022), the drafting group performs now an online consultation for the following purposes:

• Communication of the SRIA in general and the identified “Triplets of Action” in specific,
• To obtain general input, especially related to the “Triplets of Action”,
• Input regarding the urgency and timing of the “Triplets of Action”,
• To obtain suggestions for additional “Triplets of Action”.

The questionnaire will take around 30 min to be completed. The open consultation will close on 21 December 2022 and can be accessed through this link: http://enquetes.agencerecherche.fr/index.php/survey/index/sid/976696/lang/en

More information is available on the ICPerMed (https://www.icpermed.eu/en/EP-PerMed-SRIA-Consultation.php) and ERA PerMed websites and provided at the end of this email.

We would be pleased about your participation in this open consultation.

Please share this information with your colleagues and other stakeholders that might contribute with their expertise to the EP PerMed SRIA.

For any question you might have regarding the EP PerMed and the SRIA, please contact This email address is being protected from spambots. You need JavaScript enabled to view it..

Background information:

European Partnership for Personalised Medicine (EP PerMed)

The EP PerMed is one of the European research and innovation partnerships under Horizon Europe which will be dedicated to maximising the benefits of personalised medicine (PM) approaches. The European Commission and Member States have made large investments in personalised medicine over the years and this partnership builds on many of these investments. The core of the partnership is to invest in multidisciplinary, transnational research (basic, clinical, and translational) and innovation activities that will build and disseminate new knowledge, develop new technologies and methods, as well as supporting testing and piloting of the implementation of PM approaches. The partnership will work in close collaboration with other health partnerships and reach out to national, regional, and international initiatives and frameworks to ensure synergies and investments of scale. In addition, the partnership will include supportive activities contributing to policy, regulation and strengthening the field of health economics. Early this year, a draft proposal was published. At present the consortium is formed to draft the proposal for submission to the EC in April 2023. The investments from both Member States and the Commission for the 7-10 years duration of the partnership is expected to be over 300 Mio. Euros.

The EP PerMed Strategic Research and Innovation Agenda (SRIA), which is currently in preparation will guide the funding and supporting activities.

Strategic Research and Innovation Agenda (SRIA) to support the EP PerMed

All European Partnerships (EP) develop a SRIA before their launch to ensure that their long-term vision is translated into tailored roadmaps with activities, objectives and measurable outcomes.

The EP PerMed SRIA presents gaps, needs and challenges which should be addressed to maximise the benefits of Personalised Medicine approaches and ensure that there is an equal access to these approaches. The SRIA is divided into four areas of activities, “interdisciplinary research including basic, translational and clinical”, “innovation system” and “implementation” as well as “Overarching activities”. The consortium together with international experts and stakeholders have collected input and analysed reports. The drafting group, with kind support of the European Commission, organised almost 70 interviews with a diverse set of stakeholders. The interviews were translated into Triplets of Action (further explained below), where applicable.

A key element of the SRIA are the so-called Triplets of Action (challenge/objective/outcome) related to personalised medicine. The challenge/objective/outcome sequence allows to specify gaps, needs and actions in a structured and comparable way, following this definition:

Challenge:           Description of the status quo, indicate/indication what is still lacking, why this is the case and what negative consequences this has.

Objectives:          Indicates what exactly should be done to address the challenge in terms of specific actions.

Outcome:            Description of how the situation will have improved once the actions described in the objectives have been successfully implemented. 

The Triplets of Action will give an overview of needs and gaps and guide the prioritisation of challenges and subsequent actions. So far, over the different areas and chapters of the SRIA a total of 47 Triplets of Action were identified. This list is not exhaustive and open for further input and refinement.

By taking part in the open consultation launched in November 2022, participants can share their view on future activities and research for accelerating the implementation of personalised medicine approaches. Input from the whole spectrum of stakeholders and experts involved in the personalised medicine areas is encouraged, such as scientists, healthcare professionals, patients, citizens, policy advisors or individuals working in the pharma industry and biotech.

ISIDORe preparedness calls for proposals

Following its rapid research response calls for proposals dedicated to SARS-CoV-2  (still open) and Monkeypox virus (Pre-application deadline: 29 November 2022), ISIDORe (Integrated Services for Infectious Disease Outbreak Research) has launched its preparedness programme calls for proposals for free of charge access to the consortium facilities and services.

To prevent future pandemics, and advance the development of the appropriate medical countermeasures, the ISIDORe preparedness programme includes a list of priority preparedness pathogens clustered in four calls for proposals to support research on the epidemic-prone pathogens such as Risk-Group 4 pathogens (Ebola virus, Marburg virus, Nipah virus, Hendra virus, Lassa virus, “New world arenaviruses”, CCHF virus); Respiratory Pathogens (zoonotic betacoronaviruses, Influenza A, Y. Pestis, M. Tuberculosis/bovis, C. burnetii ); Vector-borne Pathogens (Rift valley fever virus, Zika virus, Chikungunya virus, West Nile virus, Dengue virus, Japanese encephalitis virus, Yellow fever virus, Tick-borne encephalitis virus, Plasmodium, B. burgdorferi, Leishmania); and other pathogens with epidemic potential (pathogen X, Orthopoxviruses, Non polio enteroviruses, Polio enteroviruses).

More information about the calls and how to apply can be found here

ISIDORe Information webinar

29 November, 2022, 10AM CET

The ISIDORe coordination team is pleased to invite you to the Information Webinar dedicated to the Preparedness calls for proposals (RG4 pathogens, Respiratory pathogens, Vector-borne pathogens, Pathogen X) launched in November 2022. It aims to provide you with information about the calls and application modalities, as well as to answer your questions.

Register here

More information can be found here